Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates for immune disorders, fibrotic diseases and cancer. Kadmon recently launched REZUROCK (belumosudil) tablets in the United States. For more information, please visit www.rezurock.com.
Data Provided by Refinitiv. Minimum 15 minutes delayed.